Agios Pharmaceuticals, Inc. (AGIO) fell 50.27%, closing at $22.62, down $22.87, following the release of topline results from its Phase 3 RISE UP trial of mitapivat in sickle cell disease.
The study met its primary endpoint: 40.6% of patients on mitapivat achieved a hemoglobin response versus 2.9% on placebo. The drug also produced statistically significant improvements in hemoglobin concentration and indirect bilirubin levels. However, it failed to achieve statistical significance for the annual rate of sickle-cell pain crises or fatigue, both key endpoints.
The company plans to meet with the U.S. Food and Drug Administration for a pre-sNDA discussion in Q1 2026 and intends to submit a marketing application thereafter. Tied to its prior thalassemia approval of PYRUKYND, the company emphasized efforts to manage costs and maintain focus on its rare-disease pipeline.
On the day of the announcement, AGIO experienced unusually heavy trading volume as investors absorbed the mixed trial findings. The stock's 52-week range is approximately $12.34 - $48.75.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.